Insmed (INSM) Fundamental Analysis: Revenue, Earnings & Valuation

1.53 / 10

Underperform

Fundamental rating is Underperform with a 1.5/10 health score. Revenue growth and receivable efficiency are positive, yet high tax burden, poor PB‑ROE, and negative asset‑MV drag performance. Overall fundamentals appear challenging.

Analysis Checks(7/10)

Total operating revenue (YoY growth rate %)

Value66.73

Score2/3

Weight0.50%

1M Return0.07%

Days sales outstanding

Value57.25

Score2/3

Weight0.86%

1M Return0.11%

Accounts receivable turnover ratio

Value6.29

Score2/3

Weight-8.21%

1M Return-1.17%

Profit-MV

Value0.66

Score2/3

Weight54.81%

1M Return6.32%

PB-ROE

Value12.90

Score0/3

Weight24.11%

1M Return2.91%

Income tax / Total profit (%)

Value-0.40

Score1/3

Weight-7.37%

1M Return-1.02%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.93

Score2/3

Weight-8.89%

1M Return-1.25%

Operating revenue (YoY growth rate %)

Value66.73

Score2/3

Weight0.46%

1M Return0.06%

Cost of sales ratio (%)

Value20.27

Score3/3

Weight9.60%

1M Return1.16%

Asset-MV

Value-0.55

Score0/3

Weight34.15%

1M Return4.19%

Is INSM undervalued or overvalued?

INSM scores 1.53/10 on fundamentals and holds a Premium valuation at present. Backed by its -249.28% ROE, -210.54% net margin, -23.49 P/E ratio, 40.59 P/B ratio, and -15.26% earnings growth, these metrics solidify its Underperform investment rating.